Gene amplification test comparison to "gold standard" to be discussed Feb. 11 at joint panel meeting.
This article was originally published in The Gray Sheet
Executive Summary
GENE AMPLIFICATION TEST COMPARISON TO "GOLD STANDARD" IN PREMARKET SUBMISSIONS is slated for discussion Feb. 11 at a joint meeting of FDA's four in vitro diagnostics advisory panels. The Microbiology Devices Panel, Clinical Chemistry and Clinical Toxicology Devices Panel, Hematology and Pathology Devices Panel, and Immunology Devices Panel all are gathering at FDA device center offices in Rockville, Maryland to provide input on "how the FDA should proceed" in the area of resolution of discrepant results "when new technology such as nucleic acid amplification is perceived to be more accurate than the reference or "gold standard" methods," according to a recent Federal Register announcement of the meeting.
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.